other material
confidence high
sentiment positive
materiality 0.55
Pyxis Oncology initiates combo trial PYX-201 + Keytruda and monotherapy expansion in HNSCC
Pyxis Oncology, Inc.
- Phase 1/2 combo trial PYX-201-102 with Keytruda (pembrolizumab) in multiple solid tumors including R/M HNSCC, HR+/HER2- BC, TNBC; first dosing on track for Q1 2025.
- Part 2 monotherapy expansion cohorts of Phase 1 PYX-201-101 began enrolling for 2L/3L R/M HNSCC patients who received prior platinum and PD-1 or EGFR and PD-1 inhibitors.
- PYX-201 is a first-in-concept ADC targeting Extradomain-B Fibronectin (EDB+FN) in tumor extracellular matrix, designed to induce immunogenic cell death.
- Combo trial is part of a Clinical Trial Collaboration Agreement with Merck (MRK).